Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.82), $0.01 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.74 million versus the consensus estimate of $10.34 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
• Kodiak Sciences Inc. (KOD) PT Lowered to $112 at Jefferies
• Lightspeed POS Inc. (LSPD)Assumed at Equalweight at Morgan Stanley